Advancement in research improves checkpoint inhibitor therapy for cancer
Researchers at Scripps Research have recently discovered that when taken with checkpoint inhibitors, the immunosuppressive medication ruxolitinib, which is licenced, enhanced T-cell responses and increased the drugs’ ability to fight cancer.
